Immunotherapy of malignant melanoma (Q35126556)

6 August 2017

1 reference

title

Immunotherapy of malignant melanoma. (English)

1 reference

6 August 2017

1 reference

2

Donald L Morton

1 reference

6 August 2017

Alan S Kadison

1

1 reference

6 August 2017

1 April 2003

1 reference

Surgical Clinics of North America

6 August 2017

1 reference

6 August 2017

83

1 reference

6 August 2017

2

1 reference

6 August 2017

343-370

1 reference

6 August 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Vaccine therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

T cell immune responses against melanoma and melanocytes in cancer and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Genotype-Phenotype Relationships in U.S. Melanoma-Prone Families With CDKN2A and CDK4 Mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Interleukin‐10 differentially regulates B7‐1 (CD80) and B7‐2 (CD86) expression on human peripheral blood dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immunologic aspects of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Adjuvants--a balance between toxicity and adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

BCG immunotherapy of malignant melanoma: summary of a seven-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Vaccines for melanoma. Design strategies and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Role of Gangliosides in Active Immunotherapy with Melanoma Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Ganglioside GM2 as a human tumor antigen (OFA-I-1)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immunogenicity of melanoma-associated gangliosides in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Targeted therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Detection of beta-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Studies of a melanoma tumor-associated antigen detected in the spent culture medium of a human melanoma cell line by allogeneic antibody. III. Physicochemical properties

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Antibody responses to melanoma/melanocyte autoantigens in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Endothelial-selectin ligands sialyl Lewis(x) and sialyl Lewis(a) are differentiation antigens immunogenic in human melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Ganglioside GM3:GD3 ratio as an index for the management of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Augmentation of IgM antibody to gp43 tumor-associated antigen peptide by melanoma cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Gangliosides of human melanoma: GM2 and tumorigenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Gangliosides of human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Recovery of a cell surface fetal antigen from circulating immune complexes of melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Tumor-associated antigen immune complexes. A potential marker of recurrent melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

M-Vax: an autologous, hapten-modified vaccine for human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900162-7

7 January 2021

10.1016/S0039-6109(02)00162-7

Identifiers

DOI

1 reference

release_wlp2eacmvjcupb4dcznudlu7xi

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wlp2eacmvjcupb4dcznudlu7xi

24 November 2022

mapped directly with Wikidata item

PubMed ID

12744613

1 reference

PubMed ID

12744613